Summary: In adult patients with diabetic foot ulcers requiring wound closure, application of polylactic acid (PLA) dermal matrix dressings demonstrated faster wound closure, improved patient quality of life, and reduced overall healthcare costs compared to collagen-based dressings as standard wound care, with no significant increase in adverse events and economic dominance as the cost-utility strategy.
| PICO | Description |
|---|---|
| Population | Adult patients with diabetic foot ulcers requiring wound closure. |
| Intervention | Application of polylactic acid (PLA) dermal matrix dressings for wound management. |
| Comparison | Use of collagen-based dressings as standard wound care for diabetic foot ulcers. |
| Outcome | PLA dressings resulted in faster wound closure, improved patient quality of life, and reduced overall healthcare costs compared to collagen dressings. No significant increase in adverse events. Cost-utility analysis demonstrated PLA as economically dominant. |
PLA matrix vs collagen dressing for diabetic foot ulcers
RCT-based cost-utility · type 2 diabetes · 31 weeks
PLA dermal matrix closed 90% of diabetic foot ulcers by 12 weeks versus 30% with collagen, healing 44% faster at roughly half the cost. It was economically dominant: better outcomes for less money.
Clinical Context
Diabetic foot ulcers (DFUs) affect approximately 15-25% of patients with diabetes during their lifetime and precede the majority of diabetes-related lower extremity amputations. The annual healthcare cost exceeds $9 billion in the United States alone. Finding cost-effective treatments that accelerate healing is a healthcare priority.
Polylactic acid (PLA) dermal matrices represent a newer approach to wound healing. PLA is a biodegradable synthetic polymer that provides structural scaffolding while degrading into lactic acid—a natural metabolite that may promote angiogenesis and tissue regeneration.
Collagen dressings have been a mainstay of advanced wound care, providing biological scaffolding derived from bovine or porcine sources. This cost-utility analysis compared these two approaches to determine which offers better value.
Clinical Pearls
1. Faster Healing Drives Cost-Effectiveness: Each week of prolonged wound healing means additional clinic visits, dressing changes, and infection risk. Faster wound closure with PLA decreases total treatment costs despite potentially higher per-unit product cost.
2. Quality of Life Improvement Is Clinically Meaningful: DFUs significantly impair quality of life through pain, restricted mobility, and anxiety about amputation. The quality-adjusted life year (QALY) gains with PLA capture these patient-centered benefits.
3. Economic Dominance Is a Strong Finding: When an intervention is both more effective AND less costly than the comparator, it is termed “economically dominant”—the strongest possible cost-effectiveness result.
4. Safety Profile Is Reassuring: The comparable adverse event rates indicate that improved efficacy doesn’t come at the cost of increased complications.
Practical Application
Consider PLA dermal matrices for wounds that have not improved with 4 weeks of standard care, wounds that are clean and well-perfused, and patients who are adherent with offloading protocols.
Document wound measurements, photographs, and healing trajectory for clinical decision-making and insurance justification. Cost-effectiveness data can support prior authorization requests when needed.
Broader Evidence Context
Cost-effectiveness analyses in wound care are increasingly important as healthcare systems face budget constraints. Advanced wound products often face coverage barriers due to high upfront costs, but products demonstrating economic dominance are most likely to receive coverage and adoption.
Study Limitations
Health economic analyses depend on cost inputs that vary by healthcare system and country. Long-term outcomes including recurrence rates not assessed. Single-center study may limit generalizability. Industry involvement in study should be considered.
Bottom Line
Polylactic acid dermal matrix dressings accelerate diabetic foot ulcer healing and are more cost-effective than collagen dressings, achieving economic dominance—better outcomes at lower cost. Consider for wounds not responding to standard care.
Source: Khorasani E, et al. “Cost-utility analysis of a polylactic acid matrix versus a collagen dressing for the closure of diabetic foot ulcers.” Read article.